The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2019 | Improved MRD response rates in CLL with obinutuzumab after ibrutinib exposure
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He discusses the results of the Bloodwise Trials Acceleration Programme (TAP) IciCLLe (ISRCTN12695354) extension study, which investigated the addition of obinutuzumab to ibrutinib in chronic lymphocytic leukemia (CLL), in patients who had and hadn’t had prior ibrutinib exposure.
